GLP-1 drugs are revolutionizing the way people eat and spend their money, according to a recent survey. The study reveals that approximately three million Canadian adults are currently taking GLP-1 medications like Ozempic or Mounjaro, and many more are interested in doing so. However, cost remains a significant barrier for potential users. The survey, conducted by Leger Healthcare, found that over half of those taking GLP-1 drugs reported a decreased appetite, and 40% mentioned reduced food cravings. This shift in eating habits is impacting their spending habits, with around 30% of users eating out or ordering takeout less frequently. As a result, they are buying more fresh fruits, vegetables, and protein-rich foods. The primary reasons for taking or considering GLP-1 medications are weight loss and diabetes management. Interestingly, more than half of those interested in the medication stated that insurance coverage or lower-cost generic options would influence their decision. The survey also highlights the body positivity movement's complex relationship with GLP-1 drugs. While some argue that these medications offer a promising solution for weight loss, others express concerns about their potential impact on the restaurant industry. The survey's findings indicate that GLP-1 drugs are no longer a niche health topic but have become a mainstream consumer and healthcare phenomenon. The effects of these drugs extend beyond prescription habits, influencing shopping behaviors and spending patterns. Additionally, the survey reveals that 35% of GLP-1 users now order smaller portions, choose healthier options, and reduce their alcohol consumption. This trend also extends to non-food purchases, with increased spending on clothing, personal care, beauty services, and fitness. The survey estimates that around two million Canadian adults are not taking GLP-1 medications but would like to. However, cost and side effects remain significant concerns. While 36% of respondents would take the medication if side effects were reduced, some experience gastrointestinal issues like nausea, vomiting, constipation, and diarrhea. More severe complications, such as gall bladder inflammation and pancreatitis, are rare, according to doctors. The survey further highlights the financial burden of GLP-1 drugs, with 25% of respondents paying for them out of pocket, despite the high monthly costs. The polling industry's professional body, the Canadian Research Insights Council, notes that online surveys like this one cannot be assigned a margin of error due to their non-random sampling method. However, a probability sample of similar size would have a margin of error of ±2.5%.
